Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Year: 2017
Type: review
Abstract: Antibodies against programmed death (PD) pathway are revolutionizing cancer immunotherapy. Currently five antibodies against PD-1/PD-L1 have been approved. The clinical use of these antibodies is rapidly expanding. Incorporation of PD antibodies into chemotherapy regimens is in active clinical investigations. The combination of pembrolizumab with carboplatin and pemetrexed has been approved for the first line therapy of metastatic non-squamous non-small cell lung cancer. Combination of PD-1/PD-L1 antibodies with small molecule inhibitors such as tyrosine kinase inhibitors and IDO inhibitors are in active clinical trials. This review summarized recent development in clinical trials of PD-1 and PD-L1 antibodies for cancer immunotherapy.
Source: Journal of Hematology & Oncology
Authors: Bingshan Liu, Yongping Song, Delong Liu
Institutions: Zhengzhou University, Henan Cancer Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,990
Award: 三氧化二砷联合环孢素治疗再生障碍性贫血的实验研究
OpenAlex ID: W2771850922
